Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

In the global, multicenter, phase 3 DESTINY-Breast09 study, Tolaney and colleagues randomly assigned 1,157 patients 1:1:1 to T-DXd plus pertuzumab (n = 383), taxane (paclitaxel or docetaxel) plus ...

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

Trastuzumab deruxtecan, often shortened to T-DXd and marketed as Enhertu, is the most potent of those ADCs so far. Until today it sat in the second-line seat, offered after the cancer outgrew the ...

Session ID: 2025-08-01:11bf0c56eb9928ece081da1 Player Element ID: vjs_video_3 ...

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally ...

The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Biologics License Application for priority review for their drug datopotamab deruxtecan, also known as Dato-DXd, for the ...

T-DXd Improves PFS in Patients With Rapid Progression on Endocrine Therapy Among patients with rapid progression (< 6 months) on first-line endocrine therapy plus cyclin-dependent kinase 4/6 ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

Daiichi Sankyo (DSKYF) stock slid 10% after the drugmaker announced it had received approval in Japan for its DXd ADC Datroway for the treatment of HR+, HER2- breast cancer.